Abiopharma

Keller Gerry adjusted position in 0.0 shares of METTLER TOLEDO INTERNATIONAL INC/ (MTD) at average price $1308.64 Filed: 2025-08-18 AccNo: 0001037646-25-000050 Size: 8 KB

New Form D - Entero Therapeutics, Inc. Filed: 2025-08-18 AccNo: 0001104659-25-079619 Size: 11 KB

New Form 144 - Voyager Therapeutics, Inc. Filed: 2025-08-18 AccNo: 0001959173-25-005261 Size: 4 KB

New Form SCHEDULE 13G - TriSalus Life Sciences, Inc. Filed: 2025-08-18 AccNo: 0001104659-25-079610 Size: 7 KB

Zai Lab Presents New Preclinical Data for ZL-1503, an IL-13/IL-31R Bispecific Antibody for the Treatment of Atopic Dermatitis, at EAACI Congress 2025

Zai Lab Presents Positive Phase 1 Data for ZL-1310, a DLL3-Targeted ADC, Demonstrating Robust Anti-Tumor Activity and Safety in Patients with Extensive-Stage Small Cell Lung Cancer at 2025 ASCO Annual Meeting

New Form SCHEDULE 13G - Cyclacel Pharmaceuticals, Inc. Filed: 2025-08-18 AccNo: 0001493152-25-012122 Size: 6 KB

Zai Lab and Novocure Announce Results From the Phase 3 PANOVA-3 Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer to be Presented at 2025 ASCO Annual Meeting

Zai Lab Announces Participation in Investor Conferences in June 2025

New Form SCHEDULE 13G - Cyclacel Pharmaceuticals, Inc. Filed: 2025-08-18 AccNo: 0001493152-25-012120 Size: 6 KB

Zai Lab Complies with the HFCAA; Not Subject to Delisting*

New Form SCHEDULE 13G - Cyclacel Pharmaceuticals, Inc. Filed: 2025-08-18 AccNo: 0001493152-25-012118 Size: 6 KB

FDA approve ARTICAINE

General Announcement::CBH RAISED S$1.98 MILLION FROM PLACEMENT BACKED BY HIGH PROFILE INVESTORS TO FUEL STRATEGIC GROWTH

Zai Lab Announces Acceptance of Biologics License Application for TIVDAK for the Treatment of Patients with Recurrent or Metastatic Cervical Cancer